Colon to Rectum

Am J Gastroenterol. 2022;117(1):100–9

Sidhu M, Forbes N, Tate DJ, Desomer L, Lee EYT, Burgess N, van Hattem A, McLeod D, Cheng E, Cartwright S, Schell A, Hilsden RJ, Heitman SJ, Bourke MJ

A randomized controlled trial of cold snare polypectomy technique: Technique matters more than snare wire diameter


Introduction: Cold snare polypectomy (CSP) is safe and effective for the removal of small adenomas (≤ 10 mm); however, reported incomplete resection rates (IRRs) vary. The optimal CSP technique, where a wide margin of normal tissue is resected around the target lesion, and snare design have both been hypothesized to reduce the IRR after CSP. The authors sought to investigate the efficacy of a thin-wire versus thick-wire diameter snare on IRR, using the standardized CSP technique.
Methods: This was an international multicenter parallel design randomized trial with 17 endoscopists of varying experience. Patients were randomized in a 1:1 ratio to the use of a thin-wire (0.30 mm) or thick-wire (0.47 mm) snare for CSP of small (≤ 10 mm) colorectal polyps. The primary end point was the IRR as determined by the histologic assessment of the defect margin after polypectomy.
Results: Over 52 months to January 2020, 1393 patients were eligible. A total of 660 patients with polyps (57.4% male) were randomized to a thin-wire (n = 339) or thick-wire (n = 321) snare. The overall IRR of the cohort was 1.5%. There was no significant difference in the IRR between the thin- and thick-wire arms (relative risk = 0.41, 95% confidence interval: 0.11–1.56; p = 0.21). No significant differences were observed in the rate of adverse events.

Discussion: In this multicenter randomized trial, cold snare polypectomy (CSP) is safe and effective with very low rates of incomplete resection independent of the diameter of the snare wire used. This suggests that the optimal operator technique is more important than the snare design alone in minimizing residual adenoma after CSP.

Prof. Dr. M.J. Bourke, Department of Gastroenterology and Hepatology, Westmead Hospital, Sydney, NSW, Australia,
E-Mail: michael@citwestgastro.com.au

and

Prof. Dr. S.J. Heitman, Department of Medicine, University of Calgary, Cumming School of Medicine, Calgary, AB, Canada,
E-Mail: steven.heitman@ucalgary.ca

DOI: DOI: 10.14309/ajg.0000000000001554

Back to overview

this could be of interest:

Lyophilized oral fecal microbiota transplantation for ulcerative colitis (LOTUS): A randomized, double-blind, placebo-controlled trial

Lancet Gastroenterol Hepatol. 2022;7(2):141–51

Antibiotic use differentially affects the risk of anti-drug antibody formation during anti-TNFα therapy in inflammatory bowel disease patients: A report from the epi-IIRN

Gut. 2022;71(2):287–95

More articles on the topic